IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BERTON GIACHETTI, PIER PAOLO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 80
NA - Nord America 26
AS - Asia 24
Totale 130
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 33
US - Stati Uniti d'America 25
IT - Italia 16
SE - Svezia 13
SG - Singapore 9
CN - Cina 5
HK - Hong Kong 4
IN - India 4
RU - Federazione Russa 4
CZ - Repubblica Ceca 3
FR - Francia 2
IE - Irlanda 2
NL - Olanda 2
BG - Bulgaria 1
CA - Canada 1
FI - Finlandia 1
GB - Regno Unito 1
HU - Ungheria 1
KR - Corea 1
NO - Norvegia 1
TW - Taiwan 1
Totale 130
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 27
Milan 6
Singapore 6
Santa Clara 5
Chandler 4
Dublin 2
Düsseldorf 2
Hong Kong 2
Hyderabad 2
Lauterbourg 2
Munich 2
Prague 2
Princeton 2
Sunapee 2
Berlin 1
Council Bluffs 1
Helsinki 1
Kent 1
Roxbury 1
Seoul 1
Shanghai 1
Shenzhen 1
Sofia 1
Southend 1
Stockholm 1
Toronto 1
Wilmington 1
Wuhan 1
Totale 80
Salva come PNG Salva come JPEG
Nome #
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations 75
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection 40
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 19
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 7
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
null 3
PARP Inhibitors for Breast Cancer Treatment 1
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 1
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 1
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 1
Totale 152
Salva come PNG Salva come JPEG
Categoria #
all - tutte 529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 529
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202228 0 0 1 7 2 2 2 2 6 2 2 2
2022/202322 5 3 2 0 1 4 1 1 1 2 2 0
2023/202422 2 1 0 6 2 0 1 3 0 1 1 5
2024/202580 6 14 6 8 7 2 0 24 13 0 0 0
Totale 152